Wall Street brokerages expect that Kamada Ltd. (NASDAQ:KMDA) will report earnings of $0.07 per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada’s earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at $0.04. Kamada reported earnings of $0.14 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is expected to report its next quarterly earnings results on Tuesday, August 7th.

According to Zacks, analysts expect that Kamada will report full-year earnings of $0.27 per share for the current year, with EPS estimates ranging from $0.18 to $0.32. For the next financial year, analysts anticipate that the company will post earnings of $0.41 per share, with EPS estimates ranging from $0.28 to $0.53. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Kamada.

Kamada (NASDAQ:KMDA) last posted its earnings results on Tuesday, May 15th. The biotechnology company reported $0.03 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.03. Kamada had a return on equity of 14.64% and a net margin of 11.17%. The company had revenue of $17.44 million for the quarter, compared to analyst estimates of $24.89 million.

A number of equities analysts have recently commented on KMDA shares. TheStreet upgraded Kamada from a “c” rating to a “b” rating in a research note on Friday, February 9th. Chardan Capital started coverage on Kamada in a research note on Friday, February 2nd. They issued a “buy” rating and a $7.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Kamada in a research note on Thursday, February 8th. Zacks Investment Research upgraded Kamada from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research note on Friday, May 18th. Finally, ValuEngine upgraded Kamada from a “sell” rating to a “hold” rating in a research note on Monday, March 19th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Kamada currently has an average rating of “Buy” and an average price target of $6.50.

A hedge fund recently bought a new stake in Kamada stock. ARK Investment Management LLC bought a new position in shares of Kamada Ltd. (NASDAQ:KMDA) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 52,695 shares of the biotechnology company’s stock, valued at approximately $251,000. ARK Investment Management LLC owned approximately 0.13% of Kamada as of its most recent SEC filing. 9.76% of the stock is owned by institutional investors.

Shares of Kamada stock remained flat at $$4.95 during trading on Friday. The stock had a trading volume of 947 shares, compared to its average volume of 18,698. The company has a quick ratio of 2.44, a current ratio of 3.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $199.30 million, a price-to-earnings ratio of 27.50 and a beta of 1.17. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61.

About Kamada

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.